Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Compass TherapeuticsCMPX 26 3-Year FCF Growth Rate is 1.50% as of Jun. 2026, which is 92% below its 10-year median of 19.20. GuruFocus rates CMPX with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 1,110 Biotechnology companies, Compass Therapeutics ranks worse than 71.62% on this metric.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 1.50% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 14.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 8 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Compass Therapeutics was 28.50% per year. The lowest was 1.10% per year. And the median was 19.20% per year.
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Compass Therapeutics 3-Year FCF Growth Rate Related Terms
CMPX vs CCCC, AVIR, STRO: 3-Year FCF Growth Rate Comparison
For the Biotechnology subindustry, Compass Therapeutics's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compass Therapeutics 3-Year FCF Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Compass Therapeutics's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Compass Therapeutics's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
Compass Therapeutics (CMPX) has a 3-Year FCF Growth Rate of 1.50% as of Jun. 2026. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Compass Therapeutics and its competitors. This is 92% below median its historical median of 19.20. Over the past decade, Compass Therapeutics' 3-Year FCF Growth Rate has ranged from 1.10 to 28.50. According to the industry distribution chart, Compass Therapeutics ranks #795 out of 1110 companies in the Biotechnology industry, placing it in the top 71.6%.
Is Compass Therapeutics' 3-Year FCF Growth Rate too high?
Compass Therapeutics' current 3-Year FCF Growth Rate of 1.50% is 92% below median its 10-year median of 19.20. Over the past 10 years, this metric has ranged from a low of 1.10 to a high of 28.50. The Biotechnology industry median 3-Year FCF Growth Rate is 19.30. Compass Therapeutics' value of 1.50% is 92.2% below this industry median. Based on the distribution chart, Compass Therapeutics ranks #795 out of 1110 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Compass Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Compass Therapeutics' 3-Year FCF Growth Rate compare to CCCC and AVIR?
According to the Biotechnology industry distribution chart, Compass Therapeutics ranks #795 out of 1110 companies for 3-Year FCF Growth Rate. This places Compass Therapeutics in the lower half of its industry. The industry median 3-Year FCF Growth Rate is 19.30. Compass Therapeutics' value of 1.50% is 92.2% below this benchmark. Historically, Compass Therapeutics' own 3-Year FCF Growth Rate has ranged from 1.10 to 28.50 over the past decade. While the company's 10-year median is 19.20 vs. the industry median of 19.30, Compass Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Biotechnology company?
The median 3-Year FCF Growth Rate among Biotechnology companies is 19.30, based on 1,110 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Compass Therapeutics's current 3-Year FCF Growth Rate of 1.50% is 92.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Compass Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year FCF Growth Rate is 19.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Compass Therapeutics's current 3-Year FCF Growth Rate is 1.50%, which is 92% below median its own 10-year median of 19.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compass Therapeutics stock overvalued right now?
Compass Therapeutics (CMPX) has a current 3-Year FCF Growth Rate of 1.50%. The current 3-Year FCF Growth Rate is 1.50%, which is 92% below median its 10-year median of 19.20 and 92.2% below the Biotechnology industry median of 19.30. Compass Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For Compass Therapeutics (CMPX), the current 3-Year FCF Growth Rate is 1.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
26GF Score
Get the complete analysis for CMPX
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMPX has been successfully added to your 
